240 related articles for article (PubMed ID: 8661335)
21. The future of drug safety testing: expanding the view and narrowing the focus.
Stevens JL; Baker TK
Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
[TBL] [Abstract][Full Text] [Related]
22. The nonclinical fertility study design for pharmaceuticals.
Lerman SA; Hew KW; Stewart J; Stump DG; Wise LD
Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):429-36. PubMed ID: 20025039
[TBL] [Abstract][Full Text] [Related]
23. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
24. Preclinical safety evaluation of recombinant human interleukin-10.
Rosenblum IY; Johnson RC; Schmahai TJ
Regul Toxicol Pharmacol; 2002 Feb; 35(1):56-71. PubMed ID: 11846636
[TBL] [Abstract][Full Text] [Related]
25. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
[TBL] [Abstract][Full Text] [Related]
27. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of preclinical toxicology studies for platinum anticancer drugs.
Clark DL; Andrews PA; Smith DD; DeGeorge JJ; Justice RL; Beitz JG
Clin Cancer Res; 1999 May; 5(5):1161-7. PubMed ID: 10353752
[TBL] [Abstract][Full Text] [Related]
29. International Conference on Harmonisation; guidance on the duration of chronic toxicity testing in animals (rodent and nonrodent toxicity testing); availability. Notice. Food and Drug Administration, HHS.
Fed Regist; 1999 Jun; 64(122):34259-60. PubMed ID: 12356093
[TBL] [Abstract][Full Text] [Related]
30. Regulatory aspects of immunotoxicology.
Schulte A; Ruehl-Fehlert C
Exp Toxicol Pathol; 2006 Jul; 57(5-6):385-9. PubMed ID: 16713214
[TBL] [Abstract][Full Text] [Related]
31. Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development?
Snodin DJ
Regul Toxicol Pharmacol; 2004 Dec; 40(3):336-55. PubMed ID: 15546688
[TBL] [Abstract][Full Text] [Related]
32. International Conference on Harmonisation; Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2006 Apr; 71(71):19193-4. PubMed ID: 16612859
[TBL] [Abstract][Full Text] [Related]
33. Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients.
Loudon PT; Blakeley DM; Boursnell ME; Day DA; Duncan IA; Lowden RC; McLean CS; Martin G; Miller JC; Shaw ML
J Gene Med; 2001; 3(5):458-67. PubMed ID: 11601759
[TBL] [Abstract][Full Text] [Related]
34. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies.
Baldrick P
Regul Toxicol Pharmacol; 2008 Jul; 51(2):230-6. PubMed ID: 18501489
[TBL] [Abstract][Full Text] [Related]
35. Regulatory forum opinion piece: obligatory microscopic examination of intermediate dose groups in non-rodent toxicity studies--is it necessary?
Weddle DL; Mahrt CR; Schmidt SP
Toxicol Pathol; 2012 Jul; 40(5):826-9. PubMed ID: 22421750
[TBL] [Abstract][Full Text] [Related]
36. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
Muller PY; Brennan FR
Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
[TBL] [Abstract][Full Text] [Related]
37. [Significance of ICH--toxicokinetics guidance and its practice--a useful approach for safety drug development].
Tsuda M; Ohno Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1997; (115):1-14. PubMed ID: 9641814
[TBL] [Abstract][Full Text] [Related]
38. Stability testing requirements for vaccines--draft guidelines of the International Conference on Harmonization.
Haase M
Dev Biol Stand; 1996; 87():309-18. PubMed ID: 8854031
[TBL] [Abstract][Full Text] [Related]
39. Developing drugs for pediatric use: a role for juvenile animal studies?
Baldrick P
Regul Toxicol Pharmacol; 2004 Jun; 39(3):381-9. PubMed ID: 15135215
[TBL] [Abstract][Full Text] [Related]
40. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
